Key facts
- Notable investors include 2048 Ventures, ARC Capital Management (New York), First Star Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Romix Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Romix Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Romix Biosciences
Developer of an AI-enabled molecular diagnostics platform designed to decode inflammation and enhance precision in healthcare and drug development. The company offers an AI-enabled, full-body, molecular scan platform, enabling customers to advance drug development, measure recovery, discover new targets, reveal biology, diagnose inflammation, measure distance to health, assess organ damage, predict complications, personalize treatment, reveal drug activity, uncover distal immune activity, monitor infection, predict treatment response and reveal the cause of inflammation.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Employees
- 2
- Website
- romixbio.com/
- Ownership
- Privately Held (backing)
Romix Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Romix Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Romix Biosciences in its N-PORT filings yet. We sweep new filings monthly.